Pharmacogenomic clinical studies
The third step involves using our understanding of the biology to guide clinical studies to understand how the genetic variants could impact on the efficacy of modern prevention and treatment strategies.
Maurice Wilkins Centre investigators evaluate the efficacy of several medicines used to treat metabolic diseases in Māori and Pacific people, with a specific focus on how genetic factors might modulate this efficacy. This work builds upon previous MWC studies of unique gene variants and drug therapies of type-2 diabetes. The goal is to use this information to understand how to better treat these conditions, potentially with therapies that are personalised to individual patients.